Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Pipeline Developments & Deals by Katana Pharmaceuticals

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Katana Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHDH.WORLD 2.1

              Participation Not Confirmed

              Update your events

              Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome

              Contact the Supplier

              Lead Product(s): Non-opioid drug

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: March of Dimes

              Deal Size: $1.1 million Upfront Cash: Undisclosed

              Deal Type: Funding June 04, 2020

              Details:

              The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).

              PharmaCompass__DigitalAd